Patients with von Willebrand disease facing minor surgery or a minor invasive procedure require pre-procedural management to ensure sufficient haemostasis and reduce the risk of bleeding complications.
The protocol targets a defined VWF activity threshold and specifies a combination haemostatic strategy to achieve it. Both the primary haemostatic intervention and an adjunctive agent are included — the full sequence, agent selection, and specifics are contained in the structured regimen.
VWF activity level ≥0.50 IU/mL
DOI: 10.1182/bloodadvances.2020003264.
In patients undergoing minor surgery or minor invasive procedures, the panel suggests increasing VWF activity levels to ≥0.50 IU/mL with desmopressin or factor concentrate with the addition of tranexamic acid over raising VWF levels to ≥0.50 IU/mL with desmopressin or factor concentrate alone (conditional recommendation based on very low certainty in the evidence of effects).
View source ↗